|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Erratum: Vol. 53, No. RR-14In the MMWR Recommendations and Reports, "Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America," in Appendix A, on page 65, an incorrect dosage was provided for infants and children with Pneumocystis jiroveci pneumonia under the column heading, "Preferred therapies and duration." The correct dosage is highlighted: "Trimethoprim-sulfamethoxazole (TMP/SMX) 15--20 mg/kg body weight TMP plus 75--100 mg/kg body weight SMX administered intravenously or by mouth in 3--4 divided doses daily (AI) (after acute pneumonitis resolved in mild-moderate disease, intravenous TMP/SMX may be changed to oral)."
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Date last reviewed: 8/3/2006 |
|||||||||
|